Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271794 | 0.79 | ESR1 (0.39) | ESR1ESR2NR1H2NR1H3ADRA2A | |
| SCHEMBL273497 | 0.79 | ESR1 (0.39) | ESR1ESR2NR1H2NR1H3ADRA2A | |
| SCHEMBL8514131 | 0.78 | ALDH1A1 (0.35) | LMNAKDM4EALDH1A1TDP1POLB | |
| SCHEMBL273488 | 0.77 | ESR1 (0.43) | ESR1ESR2NR1H2NR1H3ADRA2A | |
| SCHEMBL15735579 | 0.75 | TRPA1 (0.36) | ALDH1A1ALOX5POLB | |
| SCHEMBL14880008 | 0.75 | CA12 (0.47) | KDM4EALDH1A1TDP1POLBGAA | |
| SCHEMBL15735445 | 0.75 | ACHE (0.41) | ESR2 | |
| SCHEMBL2017485 | 0.75 | ALDH1A1 (0.41) | KDM4EALDH1A1GAA | |
| SCHEMBL13766348 | 0.72 | ESR1 (0.37) | ESR1ESR2ADRA2AADRA2CLMNA | |
| SCHEMBL9763717 | 0.72 | ESR1 (0.37) | ESR1ESR2ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341108-B1 | Surface treatment method for solid material | SHINETSU CHEMICAL CO (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8541631-B2 | Surface treatment method for solid material | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| EP-2341108-A1 | Surface treatment method for solid material | Shin-Etsu Chemical Co., Ltd. (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-20110160464-A1 | SURFACE TREATMENT METHOD FOR SOLID MATERIAL | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5670489-A | USEFUL IN TREATMENT OF DISEASES WHICH ARE MODULATED BY PROTEINS, OR IN TREATMENT OF VIRUSES SUCH AS INFLUENZA, HERPES, AND HIV | NOVARTIS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5466677-A | Dinucleoside phosphinates and their pharmaceutical compositions | CIBA-GEIGY CORPORATION (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0614907-A1 | Dinucleotide and oligonucleotide analogues | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0251827-B1 | NEW CYCLIC ETHER DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-09-15 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-5100762-A | Radiation-sensitive polymer and radiation-sensitive composition containing the same | MITSUBISHI DENKI KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
| US-4891363-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY LIMITED (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0251827-A2 | New cyclic ether derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160464-A1 | SURFACE TREATMENT METHOD FOR SOLID MATERIAL | H1-2, H1-0, HRH3 | ESR1 855/4885ESR2 1274/4885NR1H2 862/4885 |
| US-20090035215-A1 | RADIOFLUORINATION | AFF2, AFF1, NUTF2 | ESR1 1664/4885ESR2 194/4885NR1H2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.